Youzhiyou Bio-B, from Wuhan, Hubei, was successfully listed in Hong Kong
On September 25, 2023, Wuhan Youzhiyou Biopharma Co., Ltd. (hereinafter referred to as “Youzhiyou Biotech”) (02496.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
Yiming Angke, successfully listed in Hong Kong, co-sponsor by Morgan Stanley and CICC
On September 5, 2023, Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“Yiming Angke” for short) (01541.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
Kintor Pharmaceutical shares soared more than 11%
Kintor Pharmaceutical shares soared 17.51%
Kintor Pharmaceutical shares surged 147% on news of Covid-19 drug efficacy
Deqi Medicine will present five abstract wall posters at the annual meeting of the American Association for Cancer Research in 2022
Five abstracts were selected for 2022 AACR. These wall posters will introduce the progress of the company's early clinical and preclinical pipeline. The types of pipelines involved include ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. March 9, 2022 / PRNewswire /-- leading innovative biopharmaceutical company Deqi Pharmaceutical Co., Ltd. ("Deqi Pharmaceuticals", HKSE: 6996.HK), a leading innovative biopharmaceutical company in the commercial stage of R & D, production and sale of the first and / or best blood and solid tumor therapy of its kind.